1. Home
  2. XPL vs RNTX Comparison

XPL vs RNTX Comparison

Compare XPL & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solitario Resources Corp.

XPL

Solitario Resources Corp.

HOLD

Current Price

$0.79

Market Cap

74.8M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.96

Market Cap

80.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPL
RNTX
Founded
1984
2001
Country
United States
United States
Employees
N/A
10
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.8M
80.7M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
XPL
RNTX
Price
$0.79
$0.96
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$1.20
$10.00
AVG Volume (30 Days)
248.7K
475.0K
Earning Date
05-04-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
42.86
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.89
52 Week High
$0.98
$2.18

Technical Indicators

Market Signals
Indicator
XPL
RNTX
Relative Strength Index (RSI) 44.62 38.81
Support Level $0.68 N/A
Resistance Level $0.81 $1.33
Average True Range (ATR) 0.03 0.08
MACD -0.01 0.00
Stochastic Oscillator 38.27 24.28

Price Performance

Historical Comparison
XPL
RNTX

About XPL Solitario Resources Corp.

Solitario Resources Corp is an exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. Its core mineral property assets are: the Florida Canyon zinc project in Peru, the Lik zinc project in Alaska, and the Golden Crest project in South Dakota. Additionally, Solitario holds an interest in the Chambara project in Peru and also has two early-stage projects, the Cat Creek project and the Bright Angel project in Colorado. The company is conducting mineral exploration on its Golden Crest project, the Cat Creek project, and the Bright Angel project on its own.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: